- Home
- EDTK vs MRKR Comparison
EDTK vs MRKR Comparison
Compare EDTK & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- MRKR
- Stock Information
- Founded
- EDTK 2013
- MRKR N/A
- Country
- EDTK China
- MRKR United States
- Employees
- EDTK N/A
- MRKR N/A
- Industry
- EDTK Other Consumer Services
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- MRKR Health Care
- Exchange
- EDTK Nasdaq
- MRKR Nasdaq
- Market Cap
- EDTK 16.7M
- MRKR 16.6M
- IPO Year
- EDTK 2020
- MRKR N/A
- Fundamental
- Price
- EDTK $1.02
- MRKR $1.12
- Analyst Decision
- EDTK
- MRKR Strong Buy
- Analyst Count
- EDTK 0
- MRKR 2
- Target Price
- EDTK N/A
- MRKR $10.25
- AVG Volume (30 Days)
- EDTK 2.4K
- MRKR 223.4K
- Earning Date
- EDTK 08-08-2025
- MRKR 11-13-2025
- Dividend Yield
- EDTK N/A
- MRKR N/A
- EPS Growth
- EDTK N/A
- MRKR N/A
- EPS
- EDTK N/A
- MRKR N/A
- Revenue
- EDTK $893,690.00
- MRKR $4,694,988.00
- Revenue This Year
- EDTK N/A
- MRKR N/A
- Revenue Next Year
- EDTK N/A
- MRKR $9.06
- P/E Ratio
- EDTK N/A
- MRKR N/A
- Revenue Growth
- EDTK N/A
- MRKR N/A
- 52 Week Low
- EDTK $0.80
- MRKR $0.81
- 52 Week High
- EDTK $1.20
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- EDTK 45.11
- MRKR 62.25
- Support Level
- EDTK $0.95
- MRKR $0.99
- Resistance Level
- EDTK $1.08
- MRKR $1.16
- Average True Range (ATR)
- EDTK 0.04
- MRKR 0.08
- MACD
- EDTK -0.01
- MRKR 0.02
- Stochastic Oscillator
- EDTK 49.33
- MRKR 93.75
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.